Top

Journal of Radiation Oncology

Published in:

01-09-2016 | Original Research

Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable-risk prostate cancer

Authors: Michael A. Dyer, Ming-Hui Chen, Michelle H. Braccioforte, Brian J. Moran, Anthony V. D’Amico

Published in: Journal of Radiation Oncology | Issue 3/2016

Abstract

Purpose

Because survival may be shortened in prostate cancer (PC) patients with moderate/severe comorbidity receiving androgen deprivation therapy (ADT), we explored if comorbidity predicts ADT use in those with unfavorable-risk PC.

Methods

Between 10/1997 and 5/2013, 3366 men with unfavorable-intermediate- (70.7 %) or high-risk (29.3 %) PC were treated at the Chicago Prostate Cancer Center using brachytherapy with/without neoadjuvant external-beam radiation therapy (EBRT) and/or ADT. Multivariable logistic regression analysis was performed to evaluate whether history of heart failure and/or myocardial infarction (CHF/MI) was associated with decreased odds of ADT use in men with unfavorable-intermediate- or high-risk PC, adjusting for age, PC prognostic factors, year of brachytherapy, and EBRT use.

Results

Among patients with unfavorable-intermediate-risk PC, 31.2 % received ADT. Among those with high-risk PC, 38.3, 12.3, and 4.8 % received >0–6, >6–18, and >18 months of ADT, respectively. In men with unfavorable-intermediate-risk PC, history of CHF/MI was not significantly associated with decreased odds of ADT use (p = 0.49), but odds of ADT use decreased significantly over the study period, i.e., by year of brachytherapy (adjusted odds ratio [95 % confidence interval] (AOR [95%CI]) = 0.96 [0.94, 0.98], p = 0.0009). Similarly, in men with high-risk PC, history of CHF/MI was not significantly associated with odds of decreased ADT duration (all p values > 0.71), but odds of ADT use of various durations decreased over the years of the study period (AOR [95%CI] = 0.87 [0.83, 0.91], p < 0.0001; AOR [95%CI] = 0.93 [0.87, 0.99], p = 0.023; and AOR [95%CI] = 0.92 [0.83, 1.01], p = 0.089, for >0–6; >6–18; and >18 months of ADT use, respectively, compared to no ADT).

Conclusion

While neoadjuvant ADT use decreased over the study period in men with unfavorable-risk PC undergoing brachytherapy, ADT use was not less likely in those with a history of CHF/MI.

Mohler JL, Armstrong AJ, Higano CS, Rohren E, Schaeffer E, Tward J (2014) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer. http://www.nccn.org Version 1.2015

D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3):289–295. doi:10.1001/jama.299.3.289 PubMed

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365(2):107–118. doi:10.1056/NEJMoa1012348 CrossRefPubMed

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, DvEste C (2011) Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12(5):451–459. doi:10.1016/S1470-2045(11)70063-8

Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11(11):1066–1073. doi:10.1016/S1470-2045(10)70223-0 CrossRefPubMed

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. doi:10.1056/NEJMoa0810095 CrossRefPubMed

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26(15):2497–2504. doi:10.1200/JCO.2007.14.9021 CrossRefPubMed

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villa S, Perez de la Haza A, Calvo FA (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16(3):320–327. doi:10.1016/S1470-2045(15)70045-8 CrossRefPubMed

Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D’Amico AV (2015) Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. Cancer 121(16):2713–2719. doi:10.1002/cncr.29420 CrossRefPubMed

10.

Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D’Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL (2015) Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 116(3):358–365. doi:10.1111/bju.12905 CrossRefPubMed

11.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, D’Amico AV (2013) Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys 85(5):e209–e215. doi:10.1016/j.ijrobp.2012.11.039 CrossRefPubMed

12.

Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456. doi:10.1200/JCO.2006.06.2497 CrossRefPubMed

13.

D’Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW (2015) Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 314(12):1291–1293. doi:10.1001/jama.2015.8577 CrossRefPubMed

14.

Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA (2011) Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys 81(4):e335–e344. doi:10.1016/j.ijrobp.2011.04.037 CrossRefPubMed

15.

Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ (2013) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64(6):895–902. doi:10.1016/j.eururo.2013.03.033 CrossRefPubMed

16.

Hollander M, Wolfe DA (1999) Nonparametric statistical methods. Wiley series in probability and statistics texts and references section, 2nd edn. Wiley, New York

17.

Agresti A (2002) Categorical data analysis. Wiley series in probability and statistics, 2nd edn. Wiley-Interscience, New York

18.

Pagano M, Gauvreau K (2000) Principles of biostatistics, 2nd edn. Duxbury, Pacific Grove, CA

19.

Parekh A, Chen MH, D’Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL (2013) Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy 12(5):415–421. doi:10.1016/j.brachy.2013.02.005 CrossRefPubMed

20.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr.(2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291(20):2441–2447. doi:10.1001/jama.291.20.2441 CrossRefPubMed

Title: Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable-risk prostate cancer
Authors: Michael A. Dyer
Ming-Hui Chen
Michelle H. Braccioforte
Brian J. Moran
Anthony V. D’Amico
Publication date: 01-09-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 3/2016
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-016-0253-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2016

A new imaging/therapy platform by using external radionuclide (192Ir) part 2: data acquisition and analysis for breast imaging

Contemporary management of large-volume arteriovenous malformations: a clinician’s review

Three-dimensional conformal planning using low-segment multi-criteria optimization for hippocampal avoidance whole brain radiotherapy

Predictors of post-treatment symptomatic pneumonitis in lung SBRT patients through decision tree analysis

Pancreatic cancer: a review with future directions

Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer